February 27, 2015 7:18 AM ET


Company Overview of Transplant Genomics, Inc.

Company Overview

Transplant Genomics, Inc., a molecular diagnostic company, develops molecular diagnostic tests that detect early signs of graft injury, differentiate among actionable causes, and enable optimization of therapy. It focuses on improving organ transplant outcomes. The company was founded in 2013 and is based in Brookline, Massachusetts.

1501 Beacon Street

Suite 1903

Brookline, MA 02446

United States

Founded in 2013



Key Executives for Transplant Genomics, Inc.

Chief Executive Officer and President
Age: 58
Chief Clinical Advisor
Chief Scientific Advisor
Vice President of Sales
Compensation as of Fiscal Year 2014.

Transplant Genomics, Inc. Key Developments

Transplant Genomics Appoints Brett R. Jensen as Vice President of Sales

Transplant Genomics, Inc. announced the appointment of senior healthcare sales and marketing leader Brett R. Jensen to the position of Vice President, Sales. In his role, Jensen will be responsible for initiating partnerships with kidney transplant centers and overseeing the company's sales strategy as well as leading reimbursement activities. Jensen has more than 25 years of experience in business growth, organizational leadership, and product and market development in molecular diagnostics and pharmaceuticals. Prior to joining TGI, Jensen served as Sales and Marketing Director in Myriad Genetics' urology business unit. He played a key role in reimbursement for Myriad's prostate cancer genomic signature by obtaining a positive Draft Local Coverage Determination by Medicare and by achieving its inclusion in the National Comprehensive Cancer Network prostate cancer guidelines. He also held numerous sales and marketing positions at GlaxoSmithKline in a wide range of disease areas.

Transplant Genomics Announces an Exclusive License to Patent Rights Co-Owned by The Scripps Research Institute and Northwestern University

Transplant Genomics announced it has an exclusive license to patent rights co-owned by The Scripps Research Institute and Northwestern University. According to announcement, the company intends to develop and commercialize tests to monitor how well transplants are faring, and to detect and respond to early signs of problems with the graft. It first plans to focus on a test for kidney transplant recipients that can show when treatment or biopsy is required based on analysis of a patient's blood.

Similar Private Companies By Industry

Company Name Region
Retrotope, Inc. United States
Plant Sensory Systems, LLC United States
IES Diagnostics Inc. United States
Aldevron, LLC United States
Abiomed R&D, Inc. United States

Recent Private Companies Transactions

Private Placement
November 24, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Transplant Genomics, Inc., please visit www.transplantgenomics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.